Lymphoedema is chronic swelling caused by failure of the lymphatic system to drain protein-rich interstitial fluid from tissues — leading to progressive accumulation of fluid, inflammation and eventually fibrotic tissue changes. The lymphatic system normally returns approximately 10% of capillary filtrate (approximately 2-3 litres of fluid per day) back to the bloodstream. When lymphatic vessels are absent, damaged or obstructed, this fluid accumulates in the interstitium. Early lymphoedema is reversible (pitting oedema — fluid stage); late lymphoedema becomes irreversible as fibrosis and adipose tissue replace the fluid (non-pitting, indurated skin). Unlike venous oedema, lymphoedema accumulates protein-rich fluid — causing profound inflammatory changes and severe susceptibility to infection.

What causes lymphoedema?

Two main categories: Primary (congenital or genetic lymphatic dysplasia): Milroy's disease (congenital bilateral lower limb lymphoedema — VEGFR3 mutations); lymphoedema-distichiasis (pubertal onset + double eyelashes — FOXC2 mutations); Meige's disease (praecox — onset puberty-30s). Secondary (acquired lymphatic damage): Lymphatic filariasis (most common cause globally — tropical parasite infection causing progressive lymphatic obstruction); Cancer treatment (axillary or pelvic lymph node dissection + radiotherapy — most common cause in HICs; breast, gynaecological, urological, melanoma surgery); Obesity (increasingly common); Recurrent cellulitis (progressive lymphatic damage from repeated infections); Malignancy obstructing lymphatics; Surgery (inguinal, abdominal); Trauma.

What is complete decongestive therapy?

CDT is the internationally recommended gold standard for lymphoedema treatment — a two-phase structured programme. Phase 1 — Intensive decongestion (conducted by trained lymphoedema therapist, typically daily for 2-4 weeks): Manual lymphatic drainage (MLD): specialised light-touch massage redirecting lymph around blocked areas. Multi-layer compression bandaging: inelastic bandages maintaining constant pressure. Skin care: daily washing, moisturising, prevention of infection entry. Remedial exercises: muscle pump activation while bandaged. Phase 2 — Maintenance (lifelong, patient self-managed): Compression garments (worn all waking hours). Self-MLD (patient-performed). Skin care. Exercise. The goal of Phase 1: reduce limb volume. The goal of Phase 2: maintain reduced volume and prevent progression. Starting CDT before fibrosis develops (early stages) produces dramatically better outcomes.

How serious are infections in lymphoedema?

Infections are the most dangerous complication of lymphoedema and must be taken very seriously. Why lymphoedema increases infection risk: protein-rich oedema fluid provides nutrients for bacteria; lymphatic immune surveillance is impaired; skin can be stretched, cracked or traumatised. A single cellulitis episode in a lymphoedematous limb: causes rapid spreading redness, warmth, fever, severe pain; requires urgent antibiotic therapy (flucloxacillin or cefalexin oral for mild; IV antibiotics for severe or MRSA-suspected); further damages lymphatics — worsening the lymphoedema. Recurrent cellulitis (≥2 episodes per year): requires long-term prophylactic antibiotics (penicillin V 500mg twice daily or amoxicillin 500mg once daily — indefinitely). Prevention: excellent skin hygiene; moisturising; avoiding skin breaks; prompt treatment of athlete's foot; avoid insect bites; wear gloves for gardening.

What surgery exists for lymphoedema?

Surgical options are expanding: Liposuction: for stage 3 fibrotic lymphoedema — removes pathological adipose tissue that has replaced fluid. Dramatically reduces limb volume. Requires lifelong compression afterwards or fluid reaccumulates. Lymphovenous anastomosis (LVA): microsurgical connection of small lymphatic vessels directly to venules — creates a bypass for lymph drainage. Works best in early-moderate lymphoedema before fibrosis. Vascularised lymph node transfer (VLNT): transplanting healthy lymph nodes (typically from inguinal, submental or thoracic regions) to the lymphoedematous area — allows lymphangiogenesis to develop new drainage pathways. Can dramatically reduce infection rates. Sentinel lymph node biopsy (SLNB): the key PREVENTIVE surgical strategy — replacing full axillary clearance with targeted sampling in breast cancer surgery, reducing BCRL rates from approximately 25% to approximately 5%.

How does GMJ News cover lymphoedema?

GMJ News covers WHO NTD lymphatic filariasis (200M), post-cancer BCRL (15-25% breast cancer survivors), CDT gold standard, MLD, compression garments, cellulitis risk and prophylaxis, bioimpedance spectroscopy early detection, liposuction/LVA/VLNT surgery, obesity-related lymphoedema, and sentinel lymph node biopsy prevention. Lymphoedema — 250M people — is directly relevant to PHIG's cancer survivorship programme, NTD elimination agenda, and rehabilitation medicine priorities.

Home › Topics › Lymphoedema

Lymphoedema

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Lymphoedema — chronic swelling caused by dysfunction or damage to the lymphatic system resulting in protein-rich fluid accumulation in the interstitium — affects an estimated 250 million people globally, making it one of the most common chronic oedema conditions worldwide yet one of the most neglected, with the two dominant causes being: lymphatic filariasis (the most common cause globally — affecting approximately 200 million in tropical regions from Wuchereria bancrofti infection) and secondary lymphoedema from cancer treatment (particularly breast cancer axillary node dissection — affecting 15-25% of breast cancer survivors) (WHO). Complete decongestive therapy (CDT) — combining manual lymphatic drainage, compression bandaging or garments, skin care and remedial exercise — is the gold standard treatment, and physiotherapy-delivered CDT begun early dramatically reduces lymphoedema severity and prevents disease progression.

Key messages

250 million affected — one of medicine's most neglected conditions

250 million people live with lymphoedema globally — predominantly from lymphatic filariasis in tropical LMICs (approximately 200 million) and post-cancer treatment in HICs (particularly post-axillary clearance in breast cancer). Despite this enormous burden, lymphoedema remains one of the most under-resourced, under-researched and under-trained areas of clinical medicine (WHO NTD).

Primary vs secondary — fundamentally different aetiologies

Primary lymphoedema: congenital lymphatic dysplasia (aplasia, hypoplasia — Milroy's disease — VEGFR3 mutation; lymphoedema-distichiasis; Meige's disease). Secondary lymphoedema: lymphatic obstruction or damage from: lymphatic filariasis (#1 globally); cancer treatment (axillary/pelvic lymph node dissection, radiation — #1 in HICs); recurrent cellulitis; obesity; malignancy obstructing lymph flow; trauma; surgery.

CDT — complete decongestive therapy — the gold standard

Complete decongestive therapy (CDT) is the internationally recommended gold standard: Phase 1 (intensive/decongestion): daily manual lymphatic drainage (MLD) + multi-layer compression bandaging + skin care (prevent infection entry) + remedial exercise (muscle pump). Phase 2 (maintenance): compression garments (hosiery) + self-MLD + skin care + exercise. Early CDT prevents disease progression from reversible to irreversible (fibrotic) lymphoedema.

15-25% of breast cancer survivors — an underrecognised survivorship issue

Breast cancer-related lymphoedema (BCRL) — arm swelling from axillary lymph node dissection (ALND) or radiotherapy — affects approximately 15-25% of breast cancer survivors (up to 40% with full ALND vs approximately 5% with sentinel lymph node biopsy alone). Onset can be delayed by months to years post-surgery. Volume measurement (circumferential measurements, bioimpedance spectroscopy — L-Dex) at pre-operative baseline is essential for early detection.

Cellulitis — the most dangerous complication

Lymphoedema dramatically increases susceptibility to skin infections (cellulitis, erysipelas) because: protein-rich oedema fluid is an excellent bacterial culture medium; impaired lymphatic immune surveillance; skin barrier disruption from chronic swelling. Cellulitis in lymphoedematous limbs can be rapidly progressive, may require IV antibiotics, and further damages the lymphatic system — a vicious cycle. Recurrent cellulitis (≥2 episodes/year) requires long-term prophylactic penicillin V or amoxicillin.

Morbid obesity — the fastest-growing cause in HICs

Obesity-induced lymphoedema (also called phlebolymphoedema or obesity-related lymphoedema) is increasingly prevalent in HICs — predominantly affecting the lower limbs bilaterally. Obesity damages the inguinal lymph nodes (through adipose tissue pressure and inflammation) and impairs lymphatic pump function. Weight loss is the most important treatment — dramatic improvement in lymphoedema with bariatric surgery or GLP-1 agonist-assisted weight loss has been documented.

Key statistics

~250M

people affected by lymphoedema globally (WHO/ILF)

WHO/ILF

~200M

lymphatic filariasis cases — most common cause globally (WHO NTD)

WHO NTD

15-25%

of breast cancer survivors develop lymphoedema (up to 40% with full ALND)

WHO/Oncology

CDT

complete decongestive therapy — gold standard; early treatment prevents fibrosis

ILF/ISLM

≥2 episodes

cellulitis/year in lymphoedema → long-term prophylactic penicillin V indicated

BAL/ISLM

Bioimpedance

spectroscopy (L-Dex) — early lymphoedema detection before clinical swelling

ILF/ISLM

Lymphoedema causes — global burden distribution (WHO/ILF)

Source: WHO/ILF. Lymphatic filariasis dominates globally; post-cancer treatment dominates in HICs.

Glossary of key terms

Manual lymphatic drainage (MLD)
ILF/PhysiotherapyA specialised massage technique — very light skin stretching (5-40g pressure — far less than standard massage) following lymphatic pathways to redirect lymph fluid from congested regions toward functioning lymphatics and lymph nodes. Performed by trained lymphoedema therapists. Not the same as regular massage (which can worsen lymphoedema by increasing capillary filtration). Part of Phase 1 CDT (daily intensive treatment) and taught to patients as self-MLD for Phase 2 maintenance.

Lymphatic filariasis
WHO NTDCaused by parasitic roundworms — Wuchereria bancrofti (90%), Brugia malayi, B. timori — transmitted by Culex mosquitoes. Microfilariae damage lymphatic vessels over years → progressive lymphatic dysfunction → elephantiasis (extreme chronic lymphoedema of limbs, genitalia) and hydrocele. WHO Global Programme to Eliminate Lymphatic Filariasis (GPELF): mass drug administration (MDA) with diethylcarbamazine + albendazole (or ivermectin + albendazole in Africa) in endemic areas annually × 5+ years. 2024: approximately 860 million people in 47 countries at risk.

Bioimpedance spectroscopy (L-Dex)
ILF/TechnologyA technology measuring electrical impedance at multiple frequencies across the body to detect subclinical extracellular fluid accumulation in a limb — detecting lymphoedema before clinical swelling is apparent. The L-Dex score measures the impedance ratio of affected vs unaffected limb (L-Dex >7.1 units above baseline = subclinical lymphoedema). Used for prospective surveillance: baseline measurement before breast cancer surgery → serial measurements at 3, 6, 12 months → early intervention if L-Dex rises. Studies show early intervention (compression sleeves) when L-Dex rises prevents progression to clinical lymphoedema.

Liposuction for chronic fibrotic lymphoedema
Surgery/ILFIn stage 3 (irreversible fibrotic) lymphoedema where conservative CDT no longer reduces limb volume: liposuction (tumescent liposuction to remove pathological adipose tissue that has replaced displaced lymph fluid) can dramatically reduce limb volume. Not a cure — requires lifelong compression garments post-operatively. Otherwise, the lymph fluid reaccumulates and adipose tissue redevelops. Microsurgical lymphatic procedures: lymphovenous anastomosis (LVA — connecting lymphatic vessels to venules under high magnification) and vascularised lymph node transfer (VLNT) are becoming increasingly available and can reduce lymphoedema and decrease infection risk.

The International Lymphoedema Framework (ILF)
ILFAn international professional body promoting best-practice lymphoedema management, training standards for lymphoedema therapists, and research. Best Practice for the Management of Lymphoedema (ILF/MLN consensus document) — the most widely used international clinical guidelines. The ILF collaborates with WHO to address the global lymphoedema burden, particularly the 200 million affected by lymphatic filariasis.

Compression therapy in lymphoedema
ILF/ISLMCompression is the cornerstone of long-term lymphoedema management: Phase 1: multi-layer inelastic (short-stretch) bandaging — creates high working pressure during movement, low resting pressure; prevents lymph reaccumulation during intensive decongestion phase. Phase 2: made-to-measure compression hosiery (garments) — worn all waking hours; class II (23-32 mmHg) or class III (34-46 mmHg) compression; must be measured correctly and replaced every 3-6 months. Flat-knit garments (for complex limb shapes) vs round-knit (for standard shapes). Poorly fitting compression causes harm — correct fitting is essential.